» Articles » PMID: 16282088

Adult ADHD and Substance Abuse: Diagnostic and Treatment Issues

Overview
Publisher Informa Healthcare
Date 2005 Nov 12
PMID 16282088
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral, developmental disorder most often diagnosed during childhood, marked by the core symptoms of inattention, hyperactivity, and impulsivity that results in social, academic, and occupational underachievement. Although the disorder has a prevalence of 3-9% in the general childhood population and 1-5% in the general adult population, it affects between 11 and 35% of "substance-abusing" adults, oftentimes complicating treatment response. The present review discusses diagnostic assessment issues, prevalence, comorbidity, pharmacotherapy, and psychological interventions in substance-abusing adults with ADHD.

Citing Articles

Decoding the link between substance dependence and attention deficit hyperactivity disorder in adults: A cross-sectional study from North India.

Victor R, Gondwal R, Avinash P, Singhania R Ind Psychiatry J. 2024; 32(2):397-401.

PMID: 38161447 PMC: 10756592. DOI: 10.4103/ipj.ipj_47_23.


Attention-deficit hyperactivity disorder in Egyptian medical students and how it relates to their academic performance.

Shebl E, Abu Bakr Elsaid N, Hassan H, Kamal D, Araby E J Family Community Med. 2023; 30(4):287-294.

PMID: 38044975 PMC: 10688586. DOI: 10.4103/jfcm.jfcm_59_23.


Psychoactive substance use in patients diagnosed with attention-deficit/hyperactivity disorder: an exploratory study.

Wieckiewicz G, Stoklosa I, Stoklosa M, Wieckiewicz W, Gorczyca P, Gondek T Front Psychiatry. 2023; 14:1184023.

PMID: 37496681 PMC: 10366592. DOI: 10.3389/fpsyt.2023.1184023.


Stability of Attention Performance of Adults with ADHD over Time: Evidence from Repeated Neuropsychological Assessments in One-Month Intervals.

Guo N, Koerts J, Tucha L, Fetter I, Biela C, Konig M Int J Environ Res Public Health. 2022; 19(22).

PMID: 36429952 PMC: 9690645. DOI: 10.3390/ijerph192215234.


Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder.

Robinson C, Parker K, Kataria S, Downs E, Supra R, Kaye A Health Psychol Res. 2022; 10(3):38360.

PMID: 36168642 PMC: 9501833. DOI: 10.52965/001c.38360.